European Pharmaceutical Review

OCTOBER 13, 2023

BeiGene’s anti-cancer treatment is indicated for adults with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior lines of systemic therapy. if approved in follicular lymphoma – [BRUKINSA] will become the BTK inhibitor with the broadest label in the EU,” stated Dr Mobasher.

Labelling 102

Labelling 102

European Pharmaceutical Review

OCTOBER 17, 2023

In final guidance , the National Institute for Health and Care Excellence (NICE) has recommended glofitamab as a new treatment option for advanced lymphoma. NICE noted that clinical trial evidence suggests that some patients given glofitamab attained complete remission with no signs or symptoms of cancer. Data showed that 35.2

FDA 105

FDA 105

Pharmaceutical Technology

FEBRUARY 7, 2024

Avadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase I for Follicular Lymphoma.

75

75

Pharmacy Times

JANUARY 12, 2024

Experts discuss limitations and operational strategies for integrating bispecifics in DLBCL (diffuse large B cell lymphoma) treatment; addressing side effects, education, clinical pathways, and collaboration for effective patient care.

Patient Care 65

Patient Care 65

Pharmacy Times

JANUARY 9, 2024

A panel delves into pivotal clinical trials leading to therapies approved for diffuse large B-cell lymphoma (DLBCL) and provides insights on trial design, patient cohorts, response rates, duration, and toxicity profiles, highlighting efficacy nuances.

65

65

Pharmacy Times

MARCH 15, 2024

In a phase 1/2 clinical trial, lisocabtagene maraleucel helped patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) achieve complete response rates.

FDA 50

FDA 50

European Pharmaceutical Review

DECEMBER 28, 2023

In this exclusive interview, Andreas Harstrick, the Chief Medical Officer of Affimed unveils the potential of innate cell engagers for treating lymphoma. How has the treatment landscape for lymphoma evolved over the past few years?

Immunization 84

Immunization Chemotherapy Medical Schools FDA 84

Pharmaceutical Technology

APRIL 18, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Non-Hodgkin Lymphoma.

40

40

European Pharmaceutical Review

SEPTEMBER 26, 2023

Resminostat (Kinselby) has been clinically proven to postpone disease progression, new data from one of the largest clinical trials in cutaneous T-cell lymphoma (CTCL) to date has revealed. Findings from the RESMAIN study of the maintenance therapy could significantly change clinical practice in advanced CTCL” A 97.6

Labelling 95

Labelling 95

European Pharmaceutical Review

JUNE 5, 2023

Ninety-four percent of advanced stage (3 or 4) classic Hodgkin lymphoma patients treated with nivolumab, a PD-1 checkpoint inhibitor plus AVD chemotherapy (N-AVD) had one-year progression-free survival (PFS), according to Phase III trial results.

Chemotherapy 88

Chemotherapy Immunization 88

Pharmacy Times

MAY 4, 2023

The therapy had a clinically meaningful response in patients with relapsed or refractory (R/R) follicular lymphoma and R/R mantle cell lymphoma.

65

65

Pharmacy Times

NOVEMBER 28, 2023

The update followed results from the phase 1/2 EPCORE NHL-1 clinical trial evaluating the safety and preliminary efficacy of the drug, including in individuals with relapsed or refractory follicular lymphoma.

FDA 65

FDA 65

Pharmafile

DECEMBER 11, 2023

Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), which demonstrated a clinically meaningful and durable response in patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL).

59

59

Pharmacy Times

JULY 27, 2022

Pirtobrutinib is under investigation in clinical trials in patients with CLL/small lymphocytic lymphoma, mantle cell lymphoma, and non-Hodgkin lymphoma.

65

65

Fierce Pharma

JUNE 22, 2023

It's safe to say that a lack of clinical trials in a drug application raises red flags for the FDA. Aldeyra's bid for an approval in primary vitreoretinal lymphoma wasn't supported by clinical trial data as the company doesn't think a study in the rare and fatal disease is feasible, CEO Todd Brady, M.D.,

FDA 98

FDA 98

Pharmaceutical Technology

JANUARY 4, 2024

CB-010 is under clinical development by Caribou Biosciences and currently in Phase I for Follicular Lymphoma.

69

69

Hospital Pharmacy Europe

AUGUST 10, 2023

The use of atorvastatin prior to anthracycline-based chemotherapy in lymphoma patients reduces the subsequent development of cardiac dysfunction, according to the findings of a randomised trial. The number of serious related adverse events was low and similar between groups.

Chemotherapy 97

Chemotherapy Hospitals 97

Pharmacy Times

JULY 6, 2022

Clinical trial results show durable responses with mosunetuzumab in advanced follicular lymphoma.

FDA 114

FDA 114

STAT

JUNE 5, 2023

CHICAGO — Yescarta, the CAR-T therapy made by the Kite unit of Gilead Sciences, prolonged the lives of patients with large B-cell lymphoma by 27% compared to standard treatment in a long-running clinical trial, researchers reported Monday. Continue to STAT+ to read the full story…

Chemotherapy 96

Chemotherapy 96

European Pharmaceutical Review

APRIL 20, 2023

It has been nearly 20 years since a new treatment option has become available [for] newly diagnosed with diffuse large B-cell lymphoma [in the US]” The US Food and Drug Administration (FDA) has approved Polivy ® (polatuzumab vedotin-piiq) in combination with Rituxan ® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP). “It

FDA 97

FDA Immunization 97

Pharmaceutical Technology

DECEMBER 21, 2023

SGN-1 is under clinical development by Guangzhou Sinogen Pharmaceutical and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).

40

40

Pharmacy Times

JUNE 2, 2023

Obe-cel is an investigational CD19 CAR T-cell therapy currently in clinical trials for relapsed/refractory B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.

65

65

Pharmaceutical Technology

JUNE 27, 2022

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for its CD19-directed chimeric antigen receptor (CAR) T cell therapy Breyanzi (lisocabtagene maraleucel) to treat relapsed or refractory large B-cell lymphoma (LBCL) in adult patients.

FDA 105

FDA 105

European Pharmaceutical Review

FEBRUARY 8, 2023

Yescarta for blood cancer Yescarta is targeting expansions into the first line for diffuse large B-cell lymphoma (DLBCL) and second line for follicular lymphoma in 2030. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7

Labelling 97

Labelling Compounding 97

European Pharmaceutical Review

OCTOBER 31, 2022

AbbVie has announced that the European Medicines Agency (EMA) has validated its Marketing Authorisation Application (MAA) for epcoritamab, a bispecific antibody (bsAb) for adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after more than two lines of systemic therapy, offering patients a potential new therapy option.

Labelling 92

Labelling FDA 92

Pharmaceutical Technology

JANUARY 8, 2024

SYD-4228 is under clinical development by Byondis and currently in Phase I for Follicular Lymphoma.

52

52

Pharmaceutical Technology

JULY 7, 2023

AC-0676 is under clinical development by Accutar Biotechnology and currently in Phase I for Follicular Lymphoma.

75

75

Hospital Pharmacy Europe

OCTOBER 20, 2023

The NHS will fast-track the bispecific antibody glofitamab (brand name Columvi) for treating relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL) in adults after two or more systemic treatments following its recommendation by the National Institute for Health and Care Excellence (NICE).

Chemotherapy 52

Chemotherapy Immunization Hospitals 52

Pharmaceutical Technology

DECEMBER 26, 2023

NVG-111 is under clinical development by NovalGen and currently in Phase I for Mantle Cell Lymphoma.

52

52

Pharmaceutical Technology

APRIL 3, 2023

Eisai and the National Cancer Center have signed an agreement to partner on investigator-initiated clinical research for the anti-cancer agent, tazemetostat (Tazverik Tablets 200 mg), based on the Patient-Proposed Healthcare Services system.

Hospitals 98

Hospitals Insurance FDA 98

pharmaphorum

SEPTEMBER 26, 2022

Japan’s Daiichi Sankyo has claimed its first worldwide approval for Ezharmia, a first-in-class dual EZH1 and EZH2 inhibitor for the treatment of patients with relapsed or refractory adult T-cell leukaemia/lymphoma (ATL). Another from Jiangsu Hengrui Medicine (SHR2554) is still in early-stage clinical development.

Chemotherapy 98

Chemotherapy Labelling FDA 98

Pharmaceutical Technology

MAY 19, 2023

Myeloid Therapeutics has raised $73m to support the continued clinical development of its lead cell therapy programme, MT-101, in Phase I/II trials for T cell lymphoma. The financing will help to fast-track the development of other in vivo programming candidates into clinical trials.

Labelling 98

Labelling 98

Hospital Pharmacy Europe

NOVEMBER 23, 2023

Zanubrutinib (brand name Brukinsa) has been granted marketing authorisation by the European Commission (EC) for use in combination with obinutuzumab for eligible patients with follicular lymphoma, its manufacturer BeiGene has announced. The primary endpoint was overall response rate (ORR) by independent central review.

Labelling 52

Labelling Chemotherapy Hospitals 52

European Pharmaceutical Review

NOVEMBER 21, 2023

BRUKINSA ® (zanubrutinib) in combination with the anti-CD20 monoclonal antibody obinutuzumab, has been approved by the European Commission (EC) to treat relapsed or refractory follicular lymphoma in individuals who have received at least two prior lines of systemic therapy.

Labelling 98

Labelling 98

European Pharmaceutical Review

NOVEMBER 22, 2022

The US Food and Drug Administration ( FDA ) has accepted priority review of AbbVie’s Biologics License Application of epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody (BsAb), for adults with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy.

FDA 92

FDA Labelling 92

Pharmaceutical Technology

JUNE 16, 2023

Roche Group member Genentech has secured approval from the US Food and Drug Administration (FDA) for its Columvi (glofitamab-gxbm) to treat adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Columvi will be available in the US later this year.

FDA 59

FDA 59

Pharmaceutical Technology

FEBRUARY 8, 2024

Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Primary Mediastinal B-Cell Lymphoma.

40

40